- CytoSorbents ( NASDAQ: CTSO ) is trading ~4% higher premarket after it received the recommendation from the independent Data and Safety Monitoring Board to continue the Safe and Timely Antithrombotic Removal – Ticagrelor (STAR-T) trial as planned without any modifications.
- The STAR-T trial is a 120-patient, 30 center pivotal study to test the ability of DrugSorb-ATR to reduce perioperative bleeding by removing the antithrombotic agent, ticagrelor in patients undergoing cardiothoracic surgery.
- DrugSorb-ATR reduces or prevents the bleeding risk by actively removing the drug during the surgery.
- DrugSorb-ATR has received FDA Breakthrough Device Designation for this indication.
For further details see:
CytoSorbents receives recommendation from DSMB to continue trial of DrugSorb-ATR